An Introduction The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come. By Lorimer Wilson Some Background Shares of clinical-stage companies developing treatments based on psychedelic compound-based drugs moved lower in early August after the...
Our AI-Focused Drug Discovery Stocks Portfolio DOWN 8% In August
An Introduction According to research from Grand View Research, the AI-powered drug discovery process is expected to grow by a compound annual growth rate of 30% between now and 2030 and, according to Morgan Stanley, should result in as many as 50 novel therapies being brought to market by then and generate...
Our American Cannabis MSO Portfolio was DOWN 16% In August
An Introduction Last Monday, August 26th, the Drug Enforcement Administration (DEA) announced that it had scheduled an administrative hearing for December 2nd to consider differing expert opinions on the Justice Department’s proposal that cannabis be re-classified to that of a Schedule III drug under the Controlled Substances Act (CSA)....
Our Canadian Cannabis LP Portfolio Was DOWN 14% In August
An Introduction On August 26th, the Drug Enforcement Administration (DEA) announced that it had scheduled an administrative hearing for December 2nd to consider differing expert opinions on the Justice Department’s proposal that cannabis be re-classified to that of a Schedule III drug under the Controlled Substances Act (CSA). That...
Our Quantum Computing Stocks Portfolio Went DOWN 8% In August
An Introduction According to Precedence Research, the quantum computing (QC) industry is a rapidly evolving and expanding field that is expected to experience a compound annual growth rate (CAGR) of 36.9% between now and 2030. That being said, however, according to McKinsey’s estimation, operational quantum computers are only expected to...